Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Pharmacol. 2020 Sep-Oct;52(5):378-382. doi: 10.4103/ijp.IJP_549_20.
The objectives of this study were to determine the relationship between genetic polymorphisms in gene encodings for CYP3A4 and carbamazepine (CBZ)-induced dose-related side effects in North Indian people with epilepsy.
The current prospective study included 37 patients with CBZ-induced dose-related side effects and 102 patients who did not experience side effects while on CBZ. The genotyping for CYP3A4 allele (CYP3A4*16) was done using real-time polymerase chain reaction (RT-PCR) in Applied Biosystems 7500 RT-PCR System (USA). CBZ was administered in all patients at a dose varying from 15 to 20 mg/kg daily.
Various demographic variables were comparable between the groups except that control of seizures was far better in controls. After testing, it was found that none of our patients had the presence of CYP3A4*16 allele.
CYP3A4*16 allele is not represented significantly in North Indian people with CBZ-induced dose-related side effects.
本研究旨在确定 CYP3A4 基因编码的基因多态性与印度北方癫痫患者卡马西平（CBZ）诱导的剂量相关副作用之间的关系。
本前瞻性研究纳入了 37 例 CBZ 诱导的剂量相关副作用患者和 102 例未出现副作用的患者。采用实时聚合酶链反应（RT-PCR）在 Applied Biosystems 7500 RT-PCR 系统（美国）上对 CYP3A4 等位基因（CYP3A4*16）进行基因分型。所有患者均给予 15 至 20mg/kg 每日剂量的 CBZ。
除对照组的癫痫控制效果明显更好外，两组的各种人口统计学变量均无差异。检测后发现，我们的患者均不存在 CYP3A4*16 等位基因。
CYP3A4*16 等位基因在印度北方 CBZ 诱导的剂量相关副作用患者中并不显著。
